Clinical trials: Dementia Mild
Dementia Alzheimer's Type
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Primary Objective: To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC) on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to Alzheimer's disease…
- Trial name
- NCT02667496
- Testing
- Sargramostim GZ402664, Florbetapir F18
- Where
- United States
- Sponsor
- Sanofi
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Mild to Moderate Alzheimer's Disease
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT03507790
- Testing
- CT1812
- Where
- 32 sites in United States, Australia and 3 more
- Volunteers
- 153 people
- Sponsor
- Cognition Therapeutics
Alzheimer Disease
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of…
- Trial name
- NCT00506415
- Testing
- Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2
- Where
- 145 sites in United States, Canada and 5 more
- Volunteers
- 1,584 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US).
- Trial name
- NCT00916617
- Testing
- bapineuzumab
- Where
- 16 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pfizer
Alzheimer's Disease
Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients
This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with mid Alzheimer's disease
- Trial name
- NCT00795418
- Testing
- CAD106
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Novartis
Alzheimer's Disease
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102.
- Trial name
- NCT00606476
- Testing
- Bapineuzumab (AAB-001)
- Where
- 29 sites in United States
- Volunteers
- 194 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer Disease
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.
- Trial name
- NCT06427668
- Testing
- SPG302
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Spinogenix
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.
Alzheimer Disease, Mild Cognitive Impairment
A Study of NTRX-07 in Participants With Alzheimer's Disease
1. Study Overview NeuroTherapia Inc. is conducting a clinical study to explore the safety and effects of a new drug called NTRX- 07.
- Trial name
- SPPN-AD (NCT07058688)
- Testing
- NTRX-07
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 48 people
- Sponsor
- NeuroTherapia, Inc.
Alzheimer's Disease
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
- Trial name
- NCT00679627
- Testing
- Galantamine
- Where
- 95 sites in Czechia, Estonia and 10 more
- Volunteers
- 2,051 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease, Mild Cognitive Impairment
Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognition Disorders in Old Age
- Trial name
- AlzLife (NCT03657745)
- Testing
- Combination of 40Hz light and cognitive therapy (ALZLIFE)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Light LLC
Alzheimer's Disease
Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease
This proof-of-concept study will assess safety, tolerance, and efficacy of NanoLithium® NP03 in patients with mild-to-severe Alzheimer's Disease (AD).
- Trial name
- NanoLi®_AD (NCT05423522)
- Testing
- NanoLithium® NP03
- Where
- 8 sites in France
- Volunteers
- 72 people
- Sponsor
- Medesis Pharma SA
Alzheimer's Disease
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
- Trial name
- EXPEDITION 3 (NCT01900665)
- Testing
- Solanezumab
- Where
- 198 sites in United States, Australia and 9 more
- Volunteers
- 2,129 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00500500
- Testing
- EGb 761® (Tanakan®)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Ipsen
Alzheimer's Disease
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor
To establish efficacy of idalopirdine as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's disease (AD).
- Trial name
- STARBRIGHT (NCT02006654)
- Testing
- Idalopirdine
- Where
- 107 sites in United States, Australia and 13 more
- Volunteers
- 734 people
- Sponsor
- H. Lundbeck A/S
Osteoarthritis, Knee
A Telehealth Study of a Wearable Electroceutical & Sports Sleeve for Knee Osteoarthritis Pain Relief & Improved Function
The purpose of this telemedicine 24-person open-label study is to evaluate the safety and usability of a proprietary wearable microcurrent electroceutical (a device that delivers micro-ampere electronic pulses) made by Healables…
- Trial name
- HEAL01WMCOA1 (NCT04938271)
- Testing
- HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Healables Ltd.
Alzheimer's Disease
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment.
- Trial name
- NCT00663936
- Testing
- T-817MA
- Where
- 35 sites in United States, Canada
- Volunteers
- 373 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Alzheimer's Disease
Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient
Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild Alzheimer's disease or mild cognitive impairment
- Trial name
- NCT01424436
- Testing
- GSK933776
- Where
- 7 sites in Germany, Sweden
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline